1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis - Pipeline Review, H2 2020, provides an overview of the Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline landscape.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 19, 8 and 2 respectively.
Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionPost-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Development
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drug Profiles
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2020
- Number of Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by AbbVie Inc, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Acceleron Pharma Inc, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Actuate Therapeutics Inc, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by CTI BioPharma Corp, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Geron Corp, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Imago BioSciences Inc, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corp, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco SpA, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corp, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Kartos Therapeutics Inc, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Karyopharm Therapeutics Inc, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H2 2020
- Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Acceleron Pharma Inc
- Actuate Therapeutics Inc
- Bristol-Myers Squibb Co
- CTI BioPharma Corp
- F. Hoffmann-La Roche Ltd
- Geron Corp
- Imago BioSciences Inc
- Incyte Corp
- Italfarmaco SpA
- JW Pharmaceutical Corp
- Kartos Therapeutics Inc
- Karyopharm Therapeutics Inc
- MEI Pharma Inc
- Merck & Co Inc
- Millennium Pharmaceuticals Inc
- Novartis AG
- NS Pharma Inc
- Rhizen Pharmaceuticals SA
- Samus Therapeutics Inc
- Sierra Oncology Inc
- Sino Biopharmaceutical Ltd
- Sumitomo Dainippon Pharma Oncology, Inc
- Suzhou Zelgen Biopharmaceutical Co Ltd
